European Society of Cardiology
Skip navigation links
Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 
ESC Congress Reports 2011

Hot Lines and Clinical Trial Updates: reports

Live reports from the ESC Congress by some of Europe's finest cardiologists, including a selection of slides presentations and webcasts...

2012
2011
2010
Click to change congress year
Thanks to all the volunteer cardiologists who support this initiative, Congress reports are the most popular on line resource from the ESC Congress. This year, with always more sessions and new high profile sessions like Clinical Registry Highlight and State of the Art sessions, we continue to cover the best of the Congress for you.
Professor Lino Goncalves, FESC

To ensure that you receive the top scientific information ‘hot off the press,’ we have elite cardiologists reporting on their individual fields of expertise. These cardiologists are among the best from across Europe and the world and we are grateful that they are able to act as reporters for the ESC. They will cover the most important symposia, Hot Lines and trials as they happen.

Not all the sessions are available in slide format or webcasts.

Lino Goncalves, MD, PhD, FESC
Editor-in-Chief, ESC Congress Reports

Hot Lines, Clinical Trials & Registries updates reports | Pre-arranged sessions


ArticleAuthorsTopicDate
PRODIGY: Randomized comparison of six versus twenty-four months clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all comer patients undergoing percutaneous coronary intervention. Results of the PRODIGY trial. Hot Line III - Acute coronary syndromesMarco Valgimigli - Adnan KastratiPercutaneous Cardiovascular Intervention (PCI)30 Aug 2011
The RUBY-1 trial: safety, tolerability and efficacy of YM150, an oral factor Xa inhibitor, in secondary prevention of ischaemic vascular events in patients following a acute coronary syndromeHot Line III - Acute coronary syndromesPhilippe Gabriel Steg - Steen Dalby KristensenAcute Coronary Syndromes (ACS)30 Aug 2011
The EXAMINATION Trial: A randomized comparison between everolimus-eluting stent and bare metal stent in patients with ST-segment elevation myocardial infarctionHot Line III - Acute coronary syndromesManel Sabate Tenas - William WijnsPercutaneous Cardiovascular Intervention (PCI)30 Aug 2011
Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stentsHot Line III - Acute coronary syndromesLorenz Raber - Jean FajadetPercutaneous Cardiovascular Intervention (PCI)30 Aug 2011
CRISP AMI: A multi-center, randomized, controlled study of mechanical left ventricular unloading with Counterpulsation to Reduce Infarct size pre-PCI for Acute Myocardial Infarction: rationale and design of the CRISP AMI trial Hot Line III - Acute coronary syndromesManesh Patel - Kurt HuberAcute Coronary Syndromes (ACS)30 Aug 2011
EVATEL: Remote follow-up of patients implanted with an ICD: the prospective randomized EVATEL study.Hot Line II - Frontiers in interventional and device treatmentsPhilippe Mabo - Angelo AuricchioArrhythmias29 Aug 2011
ECOST: Safety of implantable cardioverter defibrillator follow-up using remote monitoring: a randomized controlled trialHot Line II - Frontiers in interventional and device treatmentsSalem Kacet - Jean-Claude DaubertArrhythmias29 Aug 2011
EMPHASIS-HF - The effect of eplerenone versus placebo on cardiovascular mortality or heart failure hospitalization in subjects with NYHA class II chronic systolic heart failure: An analysis of the High-risk groups in the study populationHot Line II - Frontiers in interventional and device treatmentsBertram Pitt - Piotr PonikowskiHeart Failure (HF)29 Aug 2011
RESET: One-year outcome of the Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent TrialHot Line II - Frontiers in interventional and device treatmentsTakeshi Kimura - Stephan WindeckerPercutaneous Cardiovascular Intervention (PCI)29 Aug 2011
Comparison of three-year outcome after PCI and CABG stratified by the SYNTAX score in patients with triple vessel coronary artery disease: an observation from the CREDO-Kyoto PCI/CABG registry Cohort-2Hot Line II - Frontiers in interventional and device treatmentsHiroki Shiomi - Frans Van de WerfPercutaneous Cardiovascular Intervention (PCI)29 Aug 2011
SMART-AV: The role of electrical delay (QLV) to predict left ventricular reverse remodeling with cardiac resynchronization therapyClinical Trial Update II - Rate and rhythmMichael R Gold - Cecilia LindeHeart Failure (HF)29 Aug 2011
PACE: Biventricular pacing superior to right ventricular pacing in bradycardia patients with preserved systolic function: two-year results of PACE trial Clinical Trial Update II - Rate and rhythmCheuk-Man Yu - Kenneth DicksteinArrhythmias29 Aug 2011
IRIS: Why does the implantable cardioverter-defibrillator not improve mortality early after myocardial infarction - Insights from the Immediate Risk Stratification Improves Survival (IRIS) trial Clinical Trial Update II - Rate and rhythmGerhard Steinbeck - Christophe LeclercqArrhythmias29 Aug 2011
SHIFT: Relationship between heart rate and health related quality of life. Results from SHIFTClinical Trial Update II - Rate and rhythmInger Ekman - Erland ErdmannHeart Failure (HF)29 Aug 2011
SHIFT: Selective heart rate reduction with Ivabradine improves left ventricular remodeling and function: insights from the SHIFT-Echocardiography sub-studyClinical Trial Update II - Rate and rhythmJean-Claude Tardif - Burkert Mathias PieskeHeart Failure (HF)29 Aug 2011
STICH: Influence of mitral valve repair on survival in the surgical treatment for Ischemic heart failure trial Clinical Trial Update II - Rate and rhythmMarek Deja - Alec VahanianHeart Failure (HF)29 Aug 2011
The Italian Elderly ACS study: Early aggressive versus initially conservative strategy in elderly patients with non-ST- elevation acute coronary syndrome: the Italian Elderly ACS randomised trial (ClinicalTrials.gov ID: NCT00510185)Clinical Registry Highlight II - Interventions and devicesStefano SavonittoAcute Coronary Syndromes (ACS)29 Aug 2011
Is clopidogrel discontinuation following acute coronary syndrome hospitalisation associated with a higher risk of death and myocardial infarction?Clinical Registry Highlight II - Interventions and devicesAdam TimmisAcute Coronary Syndromes (ACS)29 Aug 2011
DK: Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a nationwide study of 7.4 million individualsClinical Registry Highlight II - Interventions and devicesBorge NordestgaardAcute Coronary Syndromes (ACS)29 Aug 2011
The European CRT survey: 1 year follow-up resultsClinical Registry Highlight II - Interventions and devicesNigussie BogaleArrhythmias29 Aug 2011
Mitochondrial localization unveils a novel role for GRK2 in the regulation of oxidative metabolism.Basic and Translational Science Hot Line Anna FuscoClinical pharmacology29 Aug 2011
Antibody-coupling and targeting of microbubbles to activated platelets allows molecular imaging of thrombosis and monitoring of success or failure of thrombolysis using non-invasive ultrasound.Basic and Translational Science Hot Line Karlheinz PeterNon-invasive imaging: Echocardiography, MR/CT, Nuclear29 Aug 2011
Modeling of Familial Dilated Cardiomyopathy Caused by Mutation in Lamin A/C Gene Using Patient-Specific Induced Pluripotent Stem CellsBasic and Translational Science Hot Line Chung Wah SiuClinical pharmacology29 Aug 2011
A critical role for STIM1 in cardiac hypertrophyBasic and Translational Science Hot Line Jean-Sebastien HulotGenetics29 Aug 2011
Hemoglobin Directs Macrophage Differentiation and Prevents Foam Cell Formation in Human Atherosclerotic PlaquesBasic and Translational Science Hot Line Aloke FinnClinical pharmacology29 Aug 2011
miR-145: A role in the development of pulmonary arterial hypertensionBasic and Translational Science Hot Line Paola CarusoPulmonary Hypertension29 Aug 2011
PURE: The prevention gaps in 17 low, middle and high income countries involving over 150,000 peopleHot Line I - Cardiovascular risk and complicationsSalim Yusuf - Aldo Pietro MaggioniCardiovascular Disease Prevention - Risk Assessment and Management28 Aug 2011
HCS: Prospective evaluation of post-prandial triglycerides and cardiovascular events in patients with coronary artery diseaseHot Line I - Cardiovascular risk and complicationsUlrich Laufs - Philip BarterCardiovascular Disease Prevention - Risk Assessment and Management28 Aug 2011
dal-VESSEL: Efficacy and safety of dalcetrapib in patients with or at risk of coronary heart disease - the dal-VESSEL trialHot Line I - Cardiovascular risk and complicationsThomas Felix Luescher - Keith FoxCardiovascular Disease Prevention - Risk Assessment and Management28 Aug 2011
ARISTOTLE: Efficacy and safety of Apixaban compared to Warfarin for prevention of stroke and systemic embolism in 18,202 patients with atrial fibrillation: primary results of the ARISTOTLE trialHot Line I - Cardiovascular risk and complicationsChristopher B Granger - Michael D EzekowitzAtrial Fibrillation28 Aug 2011
CORP: COlchicine for Recurrent Pericarditis (CORP). A multicenter, double-blind, randomized, controlled trialHot Line I - Cardiovascular risk and complicationsMassimo Imazio - Andre KerenPericardial Disease28 Aug 2011
KYOTO HEART Study: Cardiovascular protective effects of valsartan in high-risk hypertensive patients with chronic kidney disease: updated analysis of KYOTO HEART StudyClinical Trial Update I - Drug treatmentTakahisa Sawada - Josep RedonHypertension28 Aug 2011
ASCOT: Anglo-Scandinavian Cardiac Outcomes Trial: 10 year follow-up of the Lipid lowering ArmClinical Trial Update I - Drug treatmentPeter S Sever - Guy De BackerCardiovascular Disease Prevention - Risk Assessment and Management28 Aug 2011
ARISTOTLE: Efficacy and safety of Apixaban compared to Warfarin at different levels of INR control for stroke prevention in 18,202 patients with atrial fibrillation in the ARISTOTLE trialClinical Trial Update I - Drug treatmentLars Wallentin - Jean-Philippe ColletAtrial Fibrillation28 Aug 2011
ROCKET AF: Prevention of stroke and systemic embolism using the oral direct factor Xa inhibitor Rivaroxaban compared with Warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairmentClinical Trial Update I - Drug treatmentKeith A Fox - Stefan H HohnloserAtrial Fibrillation28 Aug 2011
RE-LY: Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY®) trialClinical Trial Update I - Drug treatmentAntonio Miguel Dans - Freek VerheugtAtrial Fibrillation28 Aug 2011
ONTARGET: Medication adherence and outcomes in high-risk cardiovascular patients in the ONTARGET trialClinical Trial Update I - Drug treatmentMichael Bohm - Luigi TavazziClinical pharmacology28 Aug 2011
EUROACTION preventive cardiology programme plus intensive smoking cessation with VareniclineClinical Registry Highlight I - Risk and treatment realityDavid Allan WoodCardiovascular Disease Prevention - Risk Assessment and Management28 Aug 2011
EUROASPIRE III: modelling the clinical and cost-effectiveness of optimizing cardiovascular prevention in patients with established coronary heart disease in EuropeClinical Registry Highlight I - Risk and treatment realityLieven AnnemansCardiovascular Disease Prevention - Risk Assessment and Management28 Aug 2011
Quality of care at discharge is affected by hospital case volume in acute myocardial infarction patients. A French nationwide assessmentClinical Registry Highlight I - Risk and treatment realityFrancois SchieleCardiovascular Disease Prevention - Risk Assessment and Management28 Aug 2011
Atrial fibrillation ablation European survey: short-term results. Clinical Registry Highlight I - Risk and treatment realityJosep Brugada TerradellasAtrial Fibrillation28 Aug 2011
GARFIELD: Multicentre international registry of patients newly diagnosed with atrial fibrillation at risk of stroke: the Garfield RegistryClinical Registry Highlight I - Risk and treatment realityAjay KakkarPeripheral Arterial Diseases28 Aug 2011
Global variation in the etiology and management of atrial fibrillation: results from a global atrial fibrillation registryClinical Registry Highlight I - Risk and treatment realityJeff HealeyAtrial Fibrillation28 Aug 2011



 
Registration
2014
EuroPRevent
  8-10 May, Amsterdam
Heart Failure
  17-20 May, Athens
EuroPCR
  20-23 May, Paris
Cardiostim-EHRA 
  Europace
  18-21 June, Nice
Frontiers in 
  CardioVascular Biology

  4-6 July, Barcelona
ESC Congress
  30 Aug-3 Sep, Barcelona
Acute Cardiovascular Care
  18-20 Oct, Geneva
EuroEcho-Imaging
  3-6 Dec, Vienna